All In Biotech

Drug Trial Radar · NCT04543383

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

A Two-Part, Open-Label, Randomized, Placebo-Controlled Crossover Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jul 27, 2020

Primary completion

Jun 7, 2023

Study completion Jun 9, 2023

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 54 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as measured by changes from baselines of the coagulation testing parameters (activated partial thromboplastin time \[aPTT\] and thrombin generation assay \[TGA\]).

Conditions

  • Healthy

Interventions

  • MilvexianDrug

    Milvexian will be administered orally.

  • 4-Factor Prothrombin Complex Concentrate (4F-PCC)Biological

    4F-PCC will be administered intravenously.

  • Recombinant Human Factor VIIa (rFVIIa)Biological

    rFVIIa will be administered intravenously.

  • Placebo matching to 4F-PCCBiological

    Placebo matching to 4F-PCC will be administered intravenously.

  • Placebo matching to rFVIIaBiological

    Placebo matching to rFVIIa will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change from Baseline in Activated Partial Thromboplastin Time (aPTT)Time frame: Baseline, Day 4
  2. Part 2: Change from Baseline in aPTTTime frame: Baseline, Day 1
  3. Part 1: Change from Baseline in Endogenous Thrombin Potential (ETP) (Thrombin Generation Assay [TGA] Parameter)Time frame: Baseline, Day 4
  4. Part 1: Change from Baseline in Lag Time (TGA Parameter)Time frame: Baseline, Day 4
  5. Part 1: Change from Baseline in Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 4
  6. Part 1: Change from Baseline in Time to Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 4
  7. Part 2: Change from Baseline in ETP (TGA Parameter)Time frame: Baseline, Day 1
  8. Part 2: Change from Baseline in Lag Time (TGA Parameter)Time frame: Baseline, Day 1
  9. Part 2: Change from Baseline in Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 1
  10. Part 2: Change from Baseline in Time to Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.